evok stock: Evoke Pharma, Inc. (EVOK) Profile

Evoke Pharma, Inc. (EVOK)

evok stock refers to shares of Evoke Pharma, Inc., a Nasdaq-listed specialty pharmaceutical company trading under the ticker EVOK. This article provides a detailed, neutral company profile covering Evoke Pharma’s business focus (notably the marketed nasal formulation GIMOTI for diabetic gastroparesis), corporate history, clinical and regulatory milestones, commercial activities, financial and stock-related information, governance, intellectual property, recent news summaries, key risks, and practical pointers for following the stock and official filings. Readers will learn where to find up-to-date figures and filings and how to monitor evok stock through investor relations and market-quote platforms.

As of January 29, 2026, per Evoke Pharma investor relations and major financial quote aggregators, investors should confirm current market figures and trading data against company SEC filings and real-time market pages before making any decisions.

Company overview

Evoke Pharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for gastrointestinal (GI) disorders. Headquartered in Solana Beach, California, Evoke’s lead commercial product is GIMOTI, a metoclopramide nasal spray indicated for the treatment of symptoms of diabetic gastroparesis in adults. The company’s mission centers on improving treatment options for GI conditions through patient-friendly formulations and targeted commercialization in specialty markets.

This profile addresses evok stock from a corporate, clinical, commercial and investor perspective. It is intended to be informational and not investment advice.

History

Founding and early development

Evoke Pharma was established to advance novel formulations and delivery systems for GI-focused compounds. Early R&D prioritized a nasal formulation of metoclopramide — designed to offer a non-oral, rapid-onset route for symptomatic relief in gastroparesis — which later became GIMOTI. The company progressed from preclinical work into clinical development and later regulatory submissions aimed at U.S. approval and commercialization.

Clinical and regulatory milestones

• Development pathway: Evoke conducted phase 1 and phase 2 studies to evaluate safety, pharmacokinetics and symptomatic outcomes for its nasal metoclopramide formulation.
• Regulatory milestone: Evoke obtained U.S. regulatory clearance to market GIMOTI for adult diabetic gastroparesis symptoms. Public filings and company press releases document the FDA review milestones and approval timelines.
• Commercial launch: Following regulatory clearance, Evoke initiated commercialization activities for GIMOTI in the U.S., leveraging specialty pharmacy networks and provider education.

As with all clinical and regulatory histories, investors and readers should consult company SEC filings and official press releases for exact dates and details. As of January 29, 2026, Evoke’s investor relations materials summarize the main approval and launch milestones; readers can verify precise regulatory and clinical data in FDA and SEC documents.

Products and pipeline

Marketed product — GIMOTI

• Product: GIMOTI (metoclopramide) nasal spray.
• Indication: Approved for the treatment of symptomatic diabetic gastroparesis in adults.
• Mechanism overview: Metoclopramide is a prokinetic and antiemetic agent. The nasal formulation is intended to provide an alternative route of administration for patients who may have difficulty with oral dosing due to delayed gastric emptying or nausea.
• Patient positioning: GIMOTI is positioned as a specialty GI therapy for symptomatic relief, distributed through specialty pharmacy networks and targeted to gastroenterologists, endocrinologists, and other prescribers treating diabetic gastroparesis.

Pipeline and development programs

Evoke has historically focused on formulations that address unmet needs in GI symptom management. Any additional pipeline candidates or formulation improvements are typically described in company communications and SEC filings. For up-to-date pipeline listings and clinical trial statuses, consult the company’s investor relations materials and clinical trial registries.

Commercial operations and market access

Evoke’s commercialization approach for GIMOTI emphasizes specialty distribution and prescriber engagement. Key commercial elements include:

• Specialty pharmacy partnerships and distribution channels to support patient access and adherence.
• Provider education programs to increase awareness among gastroenterologists and diabetes care teams.
• Reimbursement strategies, prior-authorization support and payer engagement to facilitate access for eligible patients.
• Patient support services aimed at improving initiation and continuation of therapy.

Commercial performance metrics (such as prescription starts, refill rates, and net product revenue) are reported in quarterly and annual earnings releases and SEC filings. As of January 29, 2026, Evoke’s reported commercial results and management commentary are available in its most recent 10-Q/10-K filings and investor presentations; readers should review those documents for quantified sales results and trends.

Financial information

Note: The figures below are descriptive; readers should consult the latest SEC filings and official company releases for verified numbers.

• Revenue and profitability: Evoke’s revenue profile is primarily tied to GIMOTI sales and any associated licensing or partnership income. Historically, specialty pharma companies at this scale may show limited revenue during initial commercial rollout with operating losses driven by commercial build-out, R&D and corporate expenses. Verify the latest reported revenues, gross margin on product sales and net income/loss in the company’s latest Form 10-Q or Form 10-K.
• Cash position and financing: Microcap specialty pharma companies commonly manage cash runway through a combination of product revenue, equity raises, and other financing instruments. Evoke has previously completed financings to support commercialization activities; investors should check recent filings for cash balance, debt or convertible instruments and any announced equity issuances that could affect dilution.
• Guidance and outlook: Company-issued guidance (if any) and management commentary on product uptake, revenue outlook and cash runway are typically included in quarterly conference calls and investor presentations. As of January 29, 2026, consult the company’s most recent earnings release for up-to-date guidance.

Please note: This article does not present exact revenue, market cap or per-share figures. All quantitative financial metrics should be confirmed via the company’s SEC filings and up-to-date market data providers.

Stock information

• Ticker and exchange: evok stock trades under the ticker EVOK on the Nasdaq stock market.
• Real-time quotes and broker pages: Investors can monitor evok stock via major quote platforms and brokerage pages; the company’s investor relations page and SEC filings provide authoritative documentation.
• Typical trading characteristics: As a small-cap or microcap specialty pharmaceutical issuer, EVOK has historically exhibited higher intraday volatility and variability in daily volume relative to larger, established pharmaceutical companies. Volume, bid-ask spreads, and liquidity metrics vary over time.

As of January 29, 2026, per public market quote aggregators and the company’s investor relations updates, market participants should verify 52-week high/low, market capitalization and average daily volumes on live market pages.

Share structure and ownership

• Shares outstanding and float: The company’s shares outstanding, convertible securities, warrants, and restricted shares are disclosed in SEC filings. Free float is determined after accounting for restricted holdings and insider ownership.
• Institutional and insider holders: Notable institutional investors, mutual funds and insider holdings can be found in definitive proxy statements and Form 13 filings. Changes in ownership concentrations or large block trades can influence liquidity and price dynamics for evok stock.
• Recent equity activity: Any recent stock offerings, registered direct placements, warrant exercises, or conversions that affect share count and dilution are disclosed in Form 8-Ks, 10-Qs and 10-Ks.

Trading history and volatility

• Price catalysts: Clinical updates, FDA communications, payer reimbursement news, partnership announcements, and quarterly results are frequent catalysts for evok stock price movements.
• Trading events: Any trading halts, listings actions or other exchange notices relevant to EVOK would be reported by Nasdaq and summarized in company disclosures. Investors should review exchange notices and company press releases for historical trading events.

Corporate governance and management

Evoke’s board of directors and executive team oversee strategy, commercialization and regulatory activities. Typical governance disclosures include:

• Executive bios: The CEO, CFO and head of R&D/commercial lead key functions; each officer’s biography and past experience are included in SEC filings and company materials.
• Board composition: Independent directors and committee assignments (audit, compensation, governance) are disclosed in proxy statements.
• Governance practices: Policies on risk oversight, compliance, and executive compensation are described in annual reports and proxy statements.

Investor relations contact details and governance documents are available on the company’s investor relations page; as of January 29, 2026, investors should consult those official channels for up-to-date contact information and governance filings.

Intellectual property

Intellectual property rights and regulatory exclusivities materially affect the commercial prospects for GIMOTI and potential follow-on products. Relevant IP items to consider include:

• Patents: Evoke’s filed and issued patents pertaining to formulations, delivery devices and methods of use are summarized in company disclosures and patent office records.
• Regulatory listings: Patent and exclusivity information may be reflected in regulatory resources such as the FDA Orange Book when applicable. Check official FDA resources and company filings for any current patent listings associated with GIMOTI.
• Impact on exclusivity: The scope and term of patents and any applicable regulatory exclusivities influence competition timing from generic or alternative formulations.

For precise patent numbers, filing dates and expiration details, consult patent office records, the FDA Orange Book (if applicable), and the company’s disclosures. As of January 29, 2026, Evoke’s investor materials provide an IP summary; verify by reviewing the primary sources.

Recent developments and news

This section summarizes the types of news and corporate updates that have historically moved evok stock. Readers should review the company’s press release archive and SEC filings for dated details.

• Earnings and financial releases: Quarterly results and management commentary on sales progress, reimbursement, and cash position.
• Commercial milestones: Prescription volume updates, new specialty pharmacy agreements, or expanded label/indication efforts.
• Regulatory and patent updates: FDA notices, patent grants, or exclusivity-related filings.
• Partnerships and collaborations: Distribution agreements or co-promotion arrangements.

As of January 29, 2026, per company press releases and financial aggregators, investors should check the latest press release dates and SEC filings for specific announcements. Source examples include Evoke Pharma investor relations, Yahoo Finance quote pages, and industry news aggregators.

Risks and controversies

Investing in evok stock involves several risks typical of small-cap specialty pharmaceutical companies. Key considerations include:

• Market-cap and liquidity risk: Smaller market capitalizations can lead to greater price volatility and wider bid-ask spreads.
• Clinical and regulatory risk: Future label changes, post-marketing commitments, or regulatory actions can affect commercial prospects.
• Commercialization risk: Uptake of GIMOTI depends on successful provider engagement, payer coverage, and patient adherence.
• Financing and dilution risk: Continued operations may require additional financing, which can dilute existing shareholders.
• Competitive risk: Competing products, novel therapies or generics could affect market share.
• Legal and compliance risk: Patent disputes, product liability claims, or regulatory enforcement actions could materially affect operations.

This summary is not exhaustive. For a comprehensive risk disclosure, review the company’s Risk Factors section in its most recent Form 10-K and subsequent 10-Q filings.

Investment considerations

This section provides a balanced, non-investment-advice view of factors investors commonly weigh regarding evok stock:

Growth drivers

• Commercialization of GIMOTI: Successful adoption, prescription growth and payer coverage expansion are primary revenue drivers.
• IP protection: Meaningful patent coverage and regulatory exclusivity can support pricing and market share.
• Partnerships: Distribution and specialty pharmacy collaborations can accelerate access and reduce selling expenses.

Constraints and challenges

• Revenue scale: Early commercial-stage pharmaceutical firms may show limited revenue while incurring significant operating expenses.
• Dilution: Future equity raises or financing instruments may dilute shareholders.
• Execution risk: Translating approval into sustained commercial performance requires effective medical affairs, reimbursement and sales activities.

Analyst coverage and sentiment

Coverage of evok stock by sell-side analysts may be limited relative to larger pharmaceutical companies. For up-to-date analyst reports and consensus estimates (if available), consult financial data providers and company-disclosed analyst mentions. As of January 29, 2026, verify current analyst coverage on major quote platforms and in the company’s investor materials.

Reminder: This section is informational and not a recommendation. For investment decisions, consult licensed financial professionals and verify data in primary filings.

See also

• Nasal drug delivery systems
• Diabetic gastroparesis: clinical overview
• Specialty pharmaceutical commercialization strategies
• Comparable small-cap specialty pharma companies (for peer comparisons)

References

Sources used to compile this profile include company communications and standard market data aggregators. Readers should consult these primary sources directly for verification and the latest updates. Examples of referenced sources (names only):

• Evoke Pharma investor relations and SEC filings (Form 10-K, 10-Q, 8-K)
• Yahoo Finance — EVOK profile and quote pages
• Webull — EVOK quote and news aggregation
• StockTwits — EVOK community and message feed
• Brokerage profile pages and public investor platforms with EVOK listings
• Stock news aggregators summarizing EVOK press coverage

As of January 29, 2026, these sources summarized recent items cited herein. For precise dates, figures and filings, consult the original sources directly.

External links

Official places to verify filings and quotes (search for the names below):

• Evoke Pharma official website and investor relations page
• Company SEC filings (EDGAR)
• Major financial quote aggregators and brokerage quote pages (search for EVOK)

How to follow evok stock and verify data

1. Company filings: For authoritative financials and corporate actions, read Evoke Pharma’s Form 10-K and most recent Form 10-Q on the SEC filings portal.
2. Investor relations: Use the company’s investor relations materials (press releases, investor presentations, and conference call transcripts) for management commentary and dated announcements.
3. Market quotes: Monitor real-time quotes and historical charts on your brokerage platform; confirm market capitalization, 52-week ranges and average volumes before drawing conclusions.
4. News and clinical registries: For regulatory events and trial results, consult FDA notices, clinicaltrials.gov listings, and company press releases.

If you trade or monitor evok stock, consider using reputable broker platforms and stay current with company filings and regulated market notices.

Bitget note and user guidance

If you are monitoring equities alongside crypto or Web3 assets, Bitget provides market tools and a wallet solution for digital-asset users. For equity market tracking and orders, use licensed brokerage services; for Web3 wallets and digital asset custody, Bitget Wallet is a recommended option for users seeking integrated wallet features. This article remains a neutral company profile and does not constitute a recommendation to trade evok stock.

Further exploration: consult the company’s investor relations and SEC filings for the precise, up-to-date figures referenced in this profile. To track live market metrics for evok stock, use your brokerage’s real-time quote tool and the company’s most recent public filings.